Prime Medicine, Inc. (PRME)
| Market Cap | 619.52M |
| Revenue (ttm) | 4.03M |
| Net Income (ttm) | -198.37M |
| Shares Out | 180.62M |
| EPS (ttm) | -1.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,659,139 |
| Open | 3.140 |
| Previous Close | 3.180 |
| Day's Range | 3.140 - 3.450 |
| 52-Week Range | 2.280 - 6.940 |
| Beta | 2.31 |
| Analysts | Buy |
| Price Target | 6.92 (+101.75%) |
| Earnings Date | Aug 6, 2026 |
About PRME
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular in... [Read more]
Financial Performance
In 2025, Prime Medicine's revenue was $4.63 million, an increase of 55.28% compared to the previous year's $2.98 million. Losses were -$201.14 million, 2.69% more than in 2024.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for PRME stock is "Buy." The 12-month stock price target is $6.92, which is an increase of 101.75% from the latest price.
News
Prime Medicine granted RMAT designation for PM359
Prime Medicine (PRME) announced that the FDA has granted Regenerative Medicine Advanced Therapy, or RMAT, designation to PM359, an investigational autologous Prime Edited hematopoietic stem cell thera...
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359's potential to address unmet need in p4...
Prime Medicine announces New Zealand cleared trial application for PM577a
Prime Medicine (PRME) announced that the New Zealand Medicines and Medical Devices Safety Authority has cleared the Company’s Clinical Trial Application for PM577a, an investigational Prime Editor for...
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North Ameri...
Prime Medicine Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Prime Editing technology has enabled genetic cures in CGD and is advancing in vivo programs for Wilson Disease and Alpha-1 antitrypsin deficiency, with clinical data expected in 2027. The pipeline leverages modular LNP delivery and differentiated PASSIGE technology, while strong IP and partnerships support financial stability and future growth.
Prime Medicine Transcript: AGM 2026
The meeting confirmed a quorum and approved the election of two directors and the ratification of the audit firm for 2026. No questions were raised by stockholders, and all proposals passed by the required majority.
Prime Medicine Transcript: Jefferies Global Healthcare Conference 2026
Prime Editing technology is advancing with global clinical trials for Wilson's disease and Alpha-1 antitrypsin deficiency, both targeting IND/CTA filings this year and initial data in 2027. Cystic fibrosis and broader liver indications are in preclinical stages, with key catalysts including arbitration resolution and a potential BLA filing for CGD.
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine Slides: Corporate presentation
Prime Medicine has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
Prime Medicine to Present at Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie...
Prime Medicine reports Q1 EPS (28c), consensus (25c)
Reports Q1 revenue $856,000, consensus $844,220. “Prime Medicine (PRME) continues to execute with clear momentum and a focused strategy designed to deliver on the transformative potential of Prime Edi...
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie...
Prime Medicine Quarterly report: Q1 2026
Prime Medicine has published its Q1 2026 quarterly earnings report on May 7, 2026.
Prime Medicine Earnings release: Q1 2026
Prime Medicine released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Prime Medicine management to meet with Oppenheimer
Meeting to be held on May 11 hosted by Oppenheimer.
Prime Medicine Proxy statement: Proxy filing
Prime Medicine filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Prime Medicine Proxy statement: Proxy filing
Prime Medicine filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Prime Medicine appoints Makhni as Chief Financial Officer
Prime Medicine (PRME) announced the appointment of Svetlana Makhni as Chief Financial Officer, CFO. Ms. Makhni will oversee Prime Medicine’s financial operations and strategy, including investor relat...
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therap...
Oppenheimer bullish on Prime Medicine, initiates with an Outperform
As previously reported, Oppenheimer initiated coverage of Prime Medicine (PRME) with an Outperform rating and $11 price target The firm says Prime is a key name to own in the…
Prime Medicine initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Prime Medicine (PRME) with an Outperform rating and $11 price target
Prime Medicine Transcript: The Citizens Life Sciences Conference 2026
Two in vivo programs are advancing to the clinic with data expected in 2027, while a revived ex vivo program benefits from regulatory flexibility and reduced costs. Prime Editing's DNA-level correction offers broad applicability, strong safety, and competitive advantages in genetic diseases.
Prime Medicine Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing its first in vivo liver-directed clinical programs for Wilson disease and alpha-1 antitrypsin deficiency, with regulatory filings expected soon and initial clinical data anticipated in 2027. Strategic partnerships, a strong IP position, and a cash runway into 2027 support a focused pipeline and ongoing business development.
Prime Medicine reports FY25 EPS ($1.35) vs ($1.65) last year
Reports FY25 $4.632M vs $2.983M last year. “We are shaping the future of genetic medicine by advancing a platform that is rapidly emerging as the predominant gene editing technology. With…
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for PM3...